A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

Inclusion Criteria:

For Substudy 1:

• Participant who achieve clinical response in Study M14-431 or Study M14-433.

• Participant completes study procedures in the parent study. The final endoscopy forStudies M14-431 or M14-433 may be missing, if the endoscopy cannot be performedduring the COVID-19 pandemic.

For Substudy 2:

• Participant completes Substudy 1. The Week 52 endoscopy may be missing, if theendoscopy cannot be performed during the COVID-19 pandemic.

• Participant who achieved clinical response at the time described in the protocol andcompletes study procedures in the parent study/ substudy.

Exclusion Criteria:

For Substudies 1 and 2:

• Participant is considered by the investigator, for any reason, to be an unsuitablecandidate for the study.

• Participant who has a known hypersensitivity to upadacitinib or its excipients, orhad an adverse event during Studies M14-431 and M14-433 or Substudy 1 or 2 of StudyM14-430 that in the investigator's judgment makes the participant unsuitable forthis study.

• Participant at the final visit of M14-431 or M14-433 with any active or chronicrecurring infections based on the investigator's assessment that makes theparticipant an unsuitable candidate for the study. Participants with seriousinfections undergoing treatment may be enrolled BUT NOT dosed until the infectiontreatment has been completed and the infection is resolved, based on theinvestigator's assessment.

• Participants with high grade colonic dysplasia or malignancy diagnosed at theendoscopy performed at the final visit of Studies M14-431, M14-433 or Substudy 1 ofStudy M14-430 (Week 52).